标题
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 1, Pages e000356
出版商
BMJ
发表日期
2020-04-17
DOI
10.1136/jitc-2019-000356
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis
- (2020) Elizaveta Efuni et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
- (2019) Alessio Cortellini et al. ONCOLOGIST
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
- (2019) Elisabeth Perez-Ruiz et al. NATURE
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
- (2019) Jarushka Naidoo et al. Journal of the National Comprehensive Cancer Network
- Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
- (2019) Laura C. Kennedy et al. Journal of the National Comprehensive Cancer Network
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
- (2019) Douglas B. Johnson et al. NATURE MEDICINE
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
- (2019) Karthik Suresh et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis
- (2019) Yoshito Zamami et al. JAMA Oncology
- Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
- (2019) Yousef R. Badran et al. Journal for ImmunoTherapy of Cancer
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
- (2018) Karen Kelly et al. CANCER
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
- (2018) Katharina C. Kähler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Long-Term Effects of Lifestyle Intervention and Metformin during DPP on Appendicular Lean Mass
- (2018) ANN V. SCHWARTZ et al. DIABETES
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
- (2018) Michael F. Gowen et al. Journal of Translational Medicine
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab
- (2018) Yukihiro Toi et al. ONCOLOGIST
- Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
- (2018) Michael D. Richter et al. Arthritis & Rheumatology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Managing cancer risk in patients with systemic lupus erythematous
- (2018) Alexandra Ladouceur et al. Expert Review of Clinical Immunology
- Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain
- (2018) Wenbao Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
- (2018) Alice Indini et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
- (2018) Chien-Chun Steven Pai et al. JOURNAL OF CLINICAL INVESTIGATION
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Prevalence of Autoimmune Disease Among Patients With Lung Cancer
- (2016) Saad A. Khan et al. JAMA Oncology
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab in patients with melanoma and autoimmune disease
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Cell Death 1 Suppresses B-1b Cell Expansion and Long-Lived IgG Production in Response to T Cell-Independent Type 2 Antigens
- (2011) Karen M. Haas JOURNAL OF IMMUNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
- (2010) Kim L Good-Jacobson et al. NATURE IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Applications of Diabetes Antibody Testing
- (2009) Polly J. Bingley JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now